Replies to post #196715 on Biotech Values

[linhdtu]

Wouldn't that be a warning sign, at least for late buyers ?
Why would the CMO be leaving now when the company is getting down to the important P3s.

Unless one can believe that all the important decisions (dose, endpoint selections, etc ...) are all done, just a matter of execution left.

I was thinking of getting in at some point , but not with this development.